This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Li Peng, Ph.D.
Chief Scientific Officer at Palleon Pharmaceuticals

Profile

Li Peng is Chief Scientific Officer of Palleon Pharmaceuticals, a leading biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. Li has led the invention of EAGLE, CONVERGENCE, and HYDRA platform technologies and overseen research and early development at Palleon. Prior to joining Palleon, Li had worked at Medimmune/AstraZeneca for ten years in roles of increasing responsibility. She has published ~30 scientific papers and is an inventor on ~30 patents and patent applications. Li has earned a doctorate in biochemistry and molecular biology from the University of California, Davis.

Agenda Sessions

  • Engineering of Human Sialidase Neu2 as a Novel Immunotherapy for Degrading Immunosuppressive Sialoglycans to Enhance Antitumor T-Cell Immunity

    8:15am

Speakers at this event